Sequent Scientific has received its board approval to raise funds up to Rs 400 crore through the issue of GDRs/ ADRs/ FCCBs/ QIP/ such other equity-linked instruments, etc, subject to approval of members and other regulatory approvals. Further, the company has received approval to increase in the limit of investments by Foreign Institutional Investors (FIIs) in the equity share capital of the Company upto 49% of the paid up capital of the Company, subject to approval of the Members and any other statutory / regulatory approvals as may be required. The company has also received approval for increasing the Authorized Capital from Rs 40 crore to Rs 50 crore, subject to approval of Members of the Company.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
